The U.S. Food and Drug Administration declined to approve expanded use of Acadia Pharmaceuticals Inc’s antipsychotic drug for treating psychosis related to Alzheimer’s disease, the company said on Thursday. The health regulator concluded there were limitations in the interpretability of Acadia’s antipsychotic drug study and an additional study would be required, according to the company….